Black Diamond Therapeutics Q1 net income $56.5M on Servier deal; cash runway into Q4 2027

Black Diamond Therapeutics, Inc.

2025-Q1 EPS reported $0.98 revenue$70,000,000

Net income $56.5M in Q1 2025 vs net loss $18.2M in Q1 2024, driven by $70M upfront from Servier licensing deal.
Cash, cash equivalents, and investments $152.4M as of March 31, 2025, up from $98.6M at Dec 31, 2024.
Guidance: cash sufficient to fund operations into Q4 2027.
Phase 2 data for BDTX-1535 in 1L NSCLC expected Q4 2025; FDA feedback on pivotal path planned.
Global licensing agreement with Servier for BDTX-4933 includes $70M upfront and up to $710M in milestones plus royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.